Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 5/20 | 0.37 |
| ▸ | CA2 | P00918 | 5/20 | 0.37 |
| ▸ | CA7 | P43166 | 2/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 5/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.35 |
| ▸ | APLNR | P35414 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 3/20 | 0.35 |
| ▸ | CTSS | P25774 | 2/20 | 0.35 |
| ▸ | CTSK | P43235 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3486538 | 0.89 | CA1 (0.40) | TDP1CA1CA2CA7MAOA | |
| SCHEMBL5494091 | 0.86 | APLNR (0.40) | TDP1CA1CA2CA7MAOA | |
| SCHEMBL13744650 | 0.84 | CA12 (0.39) | TDP1CA1CA2CA7MAOA | |
| SCHEMBL13175001 | 0.82 | TDP1 (0.41) | TDP1CA1CA2CA7MAOA | |
| SCHEMBL12142875 | 0.82 | TDP1 (0.39) | TDP1CA1CA2CA7MAOA | |
| SCHEMBL20464123 | 0.82 | CA1 (0.43) | TDP1CA1CA2CA7MAOA | |
| SCHEMBL3709339 | 0.82 | TDP1 (0.47) | TDP1CA1CA2CA7MAOA | |
| SCHEMBL28883683 | 0.81 | LMNA (0.38) | TDP1CA1CA2CA7MAOA | |
| SCHEMBL4697256 | 0.80 | TDP1 (0.38) | TDP1CA1CA2CA7MAOA | |
| SCHEMBL1039597 | 0.80 | TDP1 (0.38) | TDP1CA1CA2CA7MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023061440-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | CULLGEN (SHANGHAI), INC. (CN) | 2023-04-20 | — | — | WO | disclosed |
| US-11180501-B2 | Crystal form of β-lactamase inhibitor and preparation method therefor | QILU PHARMACEUTICAL CO., LTD. (CN) | 2021-11-23 | — | — | US | disclosed |
| EP-3466950-B1 | NOVEL BETA-LACTAMASE INHIBITORS | QILU PHARMACEUTICAL CO LTD (CN) | 2021-02-24 | — | — | EP | disclosed |
| US-20200385385-A1 | CRYSTAL FORM OF ß-LACTAMASE INHIBITOR AND PREPARATION METHOD THEREFOR | QILU PHARMACEUTICAL CO., LTD. (CN) | 2020-12-10 | — | — | US | disclosed |
| EP-3719020-A1 | CRYSTAL FORM OF ß-LACTAMASE INHIBITOR AND PREPARATION METHOD THEREFOR | Qilu Pharmaceutical Co., Ltd (CN) | 2020-10-07 | — | — | EP | disclosed |
| US-10738051-B2 | β-lactamase inhibitors | QILU PHARMACEUTICAL CO., LTD. (CN) | 2020-08-11 | — | — | US | disclosed |
| EP-3466950-A1 | NOVEL -LACTAMASE INHIBITORS | Medshine Discovery Inc. (CN) | 2019-04-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11180501-B2 | Crystal form of β-lactamase inhibitor and preparation method therefor | NOTUM, MRPL21, BPHL | TDP1 2264/4885CA1 3718/4885CA2 4136/4885 |
| US-20200385385-A1 | CRYSTAL FORM OF ß-LACTAMASE INHIBITOR AND PREPARATION METHOD THEREFOR | NOTUM, BPHL, DCXR | TDP1 2237/4885CA1 3722/4885CA2 4102/4885 |
| US-10738051-B2 | β-lactamase inhibitors | MGAM, LCT, CEL | TDP1 3625/4885CA1 3380/4885CA2 772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.